# Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma

> **NCT03393936** · PHASE1,PHASE2 · TERMINATED · sponsor: **Shanghai PerHum Therapeutics Co., Ltd.** · enrollment: 66 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** CCT301-38
- **BIOLOGICAL:** CCT301-59

## Key facts

- **NCT ID:** NCT03393936
- **Lead sponsor:** Shanghai PerHum Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-26
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 66 (ACTUAL)
- **Why stopped:** Adjustment of study strategy
- **Last updated:** 2024-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393936, "Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03393936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*